These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

924 related articles for article (PubMed ID: 21095413)

  • 21. Medical management of lower urinary tract symptoms in men with benign prostatic enlargement.
    Marberger M
    Adv Ther; 2013 Apr; 30(4):309-19. PubMed ID: 23584673
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Pharmacological treatment of benign prostatic hyperplasia].
    Oelke M; Kuczyk MA; Herrmann TR
    Urologe A; 2009 Nov; 48(11):1365-75; quiz 1376-7. PubMed ID: 19851747
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study.
    Roehrborn CG; Siami P; Barkin J; Damião R; Major-Walker K; Nandy I; Morrill BB; Gagnier RP; Montorsi F;
    Eur Urol; 2010 Jan; 57(1):123-31. PubMed ID: 19825505
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacological therapy of benign prostatic hyperplasia/lower urinary tract symptoms: an overview for the practising clinician.
    Chapple CR
    BJU Int; 2004 Sep; 94(5):738-44. PubMed ID: 15329091
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Current benign prostatic hyperplasia treatment: impact on sexual function and management of related sexual adverse events.
    Mirone V; Sessa A; Giuliano F; Berges R; Kirby M; Moncada I
    Int J Clin Pract; 2011 Sep; 65(9):1005-13. PubMed ID: 21718399
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical practice. Benign prostatic hyperplasia and lower urinary tract symptoms.
    Sarma AV; Wei JT
    N Engl J Med; 2012 Jul; 367(3):248-57. PubMed ID: 22808960
    [No Abstract]   [Full Text] [Related]  

  • 27. Increased population use of medications for male lower urinary tract symptoms/benign prostatic hyperplasia correlates with changes in indications for transurethral resection of the prostate.
    Ingimarsson JP; Isaksson HJ; Sigbjarnarson HP; Gudmundsson J; Geirsson G
    Scand J Urol; 2014 Feb; 48(1):73-8. PubMed ID: 23924152
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Medical treatment for benign prostatic hyperplasia: Where do we stand?
    Rossanese M; Crestani A; Inferrera A; Giannarini G; Bartoletti R; Tubaro A; Ficarra V
    Urologia; 2019 Aug; 86(3):115-121. PubMed ID: 31282310
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anticholinergic therapy for lower urinary tract symptoms associated with benign prostatic hyperplasia.
    Gallegos PJ; Frazee LA
    Pharmacotherapy; 2008 Mar; 28(3):356-65. PubMed ID: 18294115
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical progression, acute urinary retention, prostate-related surgeries, and costs in patients with benign prostatic hyperplasia taking early versus delayed combination 5α-reductase inhibitor therapy and α-blocker therapy: a retrospective analysis.
    Morlock R; Goodwin B; Gomez Rey G; Eaddy M
    Clin Ther; 2013 May; 35(5):624-33. PubMed ID: 23583026
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract symptoms in men: focus on the bladder.
    Chapple CR; Roehrborn CG
    Eur Urol; 2006 Apr; 49(4):651-8. PubMed ID: 16530611
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment of lower urinary tract symptoms in benign prostatic hyperplasia and its impact on sexual function.
    Miner M; Rosenberg MT; Perelman MA
    Clin Ther; 2006 Jan; 28(1):13-25. PubMed ID: 16490576
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bloodless management of benign prostatic hyperplasia: medical and minimally invasive treatment options.
    Liatsikos E; Kyriazis I; Kallidonis P; Stolzenburg JU
    Aging Male; 2011 Sep; 14(3):141-9. PubMed ID: 21247241
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Real-world use of Permixon® in benign prostatic hyperplasia--determining appropriate monotherapy and combination treatment.
    Perry R; Milligan G; Anderson P; Gillon A; White M
    Adv Ther; 2012 Jun; 29(6):538-50. PubMed ID: 22644964
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Progression, risk factors and subsequent medical management of symptomatic benign prostatic hyperplasia.
    Pinto F; Racioppi M; Sacco E; Totaro A; Brescia A; Volpe A; Gardi M; Bassi PF
    Arch Ital Urol Androl; 2009 Mar; 81(1):1-8. PubMed ID: 19499750
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacotherapy and herbal treatment of benign prostatic hyperplasia.
    Sun J; Zhang X
    Front Biosci (Landmark Ed); 2014 Jan; 19(5):789-97. PubMed ID: 24389223
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of combined therapy with terazosin and tolteradine for patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: a prospective study.
    Yang Y; Zhao XF; Li HZ; Wang W; Zhang Y; Xiao H; Zhang X
    Chin Med J (Engl); 2007 Mar; 120(5):370-4. PubMed ID: 17376305
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Management of benign prostatic hyperplasia by the primary care physician in the 21st century: the new paradigm.
    Barkin J
    Can J Urol; 2008 Aug; 15 Suppl 1():21-30; discussion 30. PubMed ID: 18700062
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Physician perceptions of sexual dysfunction related to benign prostatic hyperplasia (BPH) symptoms and sexual side effects related to BPH medications.
    Seftel A; Rosen R; Kuritzky L
    Int J Impot Res; 2007; 19(4):386-92. PubMed ID: 17377613
    [TBL] [Abstract][Full Text] [Related]  

  • 40. BPH update: medical versus interventional management.
    Blankstein U; Van Asseldonk B; Elterman DS
    Can J Urol; 2016 Feb; 23(Suppl 1):10-5. PubMed ID: 26924590
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 47.